6 June 2017

Directorate changes


6 June 2017 Allergy Therapeutics (AIM:AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces the appointment of Dr Tunde Otulana to its Board of Directors as a Non-Executive Director with effect from 6 June 2017.


Additionally, Dr Thomas Lander has indicated that he wishes to retire from his position as a Non-Executive Director of the Group with effect from 30 June 2017.


Dr Babatunde ‘Tunde’ Adekunle Otulana, aged 60, brings over 20 years’ pharmaceutical industry knowledge and significant executive level experience in clinical development and medical affairs roles. He currently serves as Senior Vice President and Chief Medical Officer at Mallinckrodt Pharmaceuticals where he has responsibility for all global medical functions, and has previously worked for Boehringer Ingelheim Pharmaceutical Inc. as Senior Vice President, Clinical Development and Medical Affairs. He has previously spent over six years working at the US Food and Drug Administration (FDA) as a Medical Officer and Medical Team Leader in the Division of Pulmonary-Allergy Drug Products.


Dr Otulana received his medical degree in Nigeria where he also completed hospital residency training. He then moved to Cambridge, UK to complete his Clinical Research Fellowship in Pulmonary Medicine at the Papworth and Addenbrooke’s hospitals, University of Cambridge.


“We are pleased to welcome Tunde to the Board. He brings a wealth of global experience in clinical and regulatory work, particularly with the FDA in the United States, which will be especially valuable as we continue to execute our global strategy. “I also want to take this opportunity to thank Thomas for his significant contribution and support to the Group during the past five years. Thomas has always given the Board very clear advice on R&D matters and his experience has been hugely valuable. We all wish him well for the future in his retirement.”

Peter Jensen

Chairman of Allergy Therapeutics

Allergy Therapeutics confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Dr Otulana’s appointment.


For further information, please contact:


Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director


Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking


Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan



Notes for editors:


About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Group sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.


Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Group employs c.495 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.


Back to previous page